Evidence map›Paper›PMID 40279671›Full record

ArticleThe Journal of cell biology2025

A multifunction murine Col4a1 allele reveals potential gene therapy parameters for Gould syndrome.

Mao Mao, Yoshihiro Ishikawa, Cassandre Labelle-Dumais, Xiaowei Wang, Yien-Ming Kuo, Uma B Gaffney, Megan E Smith, Carlie N Abdala, Matthew D Lebedev, William J Paradee and 1 more

Abstract read
In one paragraph

Article in The Journal of cell biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Mao MaoDepartment of Ophthalmology, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0001-7026-5790
Yoshihiro IshikawaDepartment of Ophthalmology, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0003-2013-0518
Cassandre Labelle-DumaisDepartment of Ophthalmology, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0002-2134-2240
Xiaowei WangDepartment of Ophthalmology, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0002-5175-7623
Yien-Ming KuoDepartment of Ophthalmology, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0001-9925-3013
Uma B GaffneyDepartment of Ophthalmology, University of California San Francisco, San Francisco, CA, USA.ORCID 0009-0002-7372-6833
Megan E SmithDepartment of Ophthalmology, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0002-5679-9136
Carlie N AbdalaDepartment of Ophthalmology, University of California San Francisco, San Francisco, CA, USA.ORCID 0009-0000-1990-4227
Matthew D LebedevDepartment of Ophthalmology, University of California San Francisco, San Francisco, CA, USA.ORCID 0009-0002-9181-3244
William J ParadeeGenome Editing Core Facility, University of Iowa, Iowa City, IA, USA.ORCID 0009-0009-1761-5961
Douglas B GouldDepartment of Ophthalmology, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0001-5127-5328

Funding

Rapid-Prototyping and Design CoreP30EY002162 · NEI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ULLIAN, ERIK M · 1985 to 2024
$16.8M
Gene therapy for disorders of the extracellular matrixRF1NS128217 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GOULD, DOUGLAS, MUSOLINO, PATRICIA L · 2023 to 2023
$2.5M
Characterization of Tagged Type IV CollagenR21NS133610 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GOULD, DOUGLAS · 2023 to 2023
$444k
Chemical Biology Approaches to Studying Collagen IV StabilityR21EY035366 · NEI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GESTWICKI, JASON E · 2023 to 2023
$436k
All May See FoundationNational Institue of Neurological Disease and StrokeNEI NIH HHS P30 EY002162NEI NIH HHS R21 EY035366NIH HHS 1R21NS133610NINDS NIH HHS R21 NS133610NINDS NIH HHS RF1 NS128217Research to Prevent Blindness
6 · The paper itself

Abstract

Basement membranes (BMs) are specialized extracellular matrix (ECM) structures essential for organ morphogenesis, architecture, and function. BM composition and properties vary between tissues, developmental stages, and disease states, and there is only a rudimentary understanding of BM dynamics. Here, we introduce a versatile mouse model carrying a multifunctional dual-color fluorescence tagged allele with knockout potential for the fundamental BM component type IV collagen alpha 1 (COL4A1). This allele enables the characterization of cell type- and time-specific contributions to BMs and the generation of a conditional Col4a1 null allele. We demonstrate the utility of this unique genetic resource in providing clinically relevant insights for individuals with Gould syndrome - a multisystem disorder caused by COL4A1 and COL4A2 mutations. We show active COL4A1 turnover in postnatal cerebrovascular BMs, identifying a potential interventional window for cerebrovascular manifestations associated with Gould syndrome. We also demonstrate that heterozygous Col4a1 deletion is significantly less pathogenic than dominant Col4a1 missense mutations, which has important implications for gene therapy.

Indexed as

Basement MembraneCollagen Type IVGenetic TherapyAllelesAnimalsDisease Models, AnimalHumansMiceMice, KnockoutCol4a1 protein, mouseCollagen Type IV

Identifiers

PMID40279671
PMCPMC12029515

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.